Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
MV BioTherapeutics SA
About
  2. Companies
  3. MV BioTherapeutics SA
  4. News
  5. New company name and website

New company name and website

SHARE
May. 14, 2020
Courtesy ofMV BioTherapeutics SA

We are proud to announce the launch of the company website that provides most relevant information on the technology and pipeline of MV BioTherapeutics. We have changed the original name of the company from MicroVaccines to MV BioTherapeutics (from now on MV).

“During the past years we have developed therapeutic live biotherapeutics with different mode of action as compared to the original live attenuated microbial vaccines, which were exemplified as microvaccines” says Dr. Fabio Grassi, founder and Chairman of MV.

“With two lead indications and potential future developments of this promising application, it was important to characterize the company as non-exclusively dedicated to vaccines that is a very specific pharmaceutical area.”

The abbreviation MV is directly related to the two patented microorganisms ApyraMed® and ApyraVax®

About MV BioTherapeutics
MV BioTherapeutics is a Swiss microbiome biotherapeutics company founded in 2018 as a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona. The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications:
  1. ApyraVax with the lead indication of Clostridioides difficile infection
  2. ApyraMed with lead indications as immune modulator in cancer and beneficial for the gut ecosystem

Research experiments and preclinical trials are performed in the research lab hosted at IRB. The company is looking for seed funding in order to move forward as a fully operational company into clinics with the main indications.

Contact supplier

Drop file here or browse